Constantinos Bakogiannis, Dimitrios Mouselimis, Anastasios Tsarouchas, Christodoulos E Papadopoulos, Efstratios K Theofillogiannakos, Elmira Lechat, Antonios P Antoniadis, Efstathios D Pagourelias, Ioannis Kelemanis, Stergios Tzikas, Nikolaos Fragakis, Georgios K Efthimiadis, Theodoros D Karamitsos, Michael Doumas, Vassilios P Vassilikos
AIMS: The Iron Intravenous Therapy in Reducing the burden of Severe Arrhythmias in HFrEF (RESAFE-HF) registry study aims to provide real-word evidence on the impact of intravenous ferric carboxymaltose (FCM) on the arrhythmic burden of patients with heart failure with reduced ejection fraction (HFrEF), iron deficiency (ID), and implanted cardiac implantable electronic devices (CIEDs). METHODS AND RESULTS: The RESAFE-HF (NCT04974021) study was designed as a prospective, single-centre, and open-label registry study with baseline, 3, 6, and 12 month visits...
January 17, 2023: ESC Heart Failure